Siponimod

Siponimod is an agonist of sphingosine-1-phosphate receptor 1 (S1P1) and S1P5. It is selective for S1P1 and S1P5 over S1P2, S1P3, and S1P4 (EC50s = 0.39, 0.98, >10,000, >1,000, and 750 nM, respectively, in GTP-gammaS binding assays). Siponimod (10 nM) reduces demyelination induced by lysophosphatidylcholine or psychosine (Cay-31594, Cay-20338) in mouse organotypic cerebellar slice cultures. It decreases plasma levels of urea and creatinine in a rat model of renal ischemia-reperfusion injury when administered at doses of 10 and 30 mg/kg. Siponimod (0.3 and 3 mg/kg) reduces disease severity in a rat model of experimental autoimmune encephalomyelitis (EAE). Formulations containing siponimod have been used in the treatment of multiple sclerosis.Formal Name: 1-[[4-[(1E)-1-[[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]imino]ethyl]-2-ethylphenyl]methyl]-3-azetidinecarboxylic acid. CAS Number: 1230487-00-9. Synonyms: BAF312. Molecular Formula: C29H35F3N2O3. Formula Weight: 516.6. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 16 mg/ml, DMSO: 20 mg/ml, DMSO:PBS (pH 7.2) (1:20): 0.04 mg/ml, Ethanol: 3 mg/ml. lambdamax: 260 nm. SMILES: CCC1=CC(/C(C)=N/OCC2=CC=C(C3CCCCC3)C(C(F)(F)F)=C2)=CC=C1CN4CC(C(O)=O)C4. InChi Code: InChI=1S/C29H35F3N2O3/c1-3-21-14-23(10-11-24(21)15-34-16-25(17-34)28(35)36)19(2)33-37-18-20-9-12-26(22-7-5-4-6-8-22)27(13-20)29(30,31)32/h9-14,22,25H,3-8,15-18H2,1-2H3,(H,35,36)/b33-19+. InChi Key: KIHYPELVXPAIDH-HNSNBQBZSA-N.